Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Relapse represents the main cause of treatment failure after stem cell transplantation (SCT). Thus, monitoring of minimal residual disease (MRD) in allografted patients allows an early detection of recurrence and a subsequent intervention prior to clinically detectable relapse. MRD assessment by polymerase chain reaction-based methods is currently part of the routine clinical management of patients with chronic myeloid leukemia after allo-SCT. It is also recognized that it is a useful prognostic tool in several mature lymphoid and plasma cell disorders such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. In some of these entities, clinical trials employing MRD as a decision-making tool are currently ongoing and will define whether sensitive MRD detection allows for earlier therapeutic intervention to improve the outcome of SCT. We here discuss the methods of MRD evaluation in lymphoid and plasma cell disorders following transplantation with the ultimate aim of providing critical information for the setup of molecular approaches to detect MRD.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
Pages209-237
Number of pages29
Volume1109
DOIs
Publication statusPublished - 2014

Publication series

NameMethods in Molecular Biology
Volume1109
ISSN (Print)10643745

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders'. Together they form a unique fingerprint.

  • Cite this